This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:diseases [01.03.2012] – external edit 127.0.0.1 | home:diseases [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 9: | Line 9: | ||
Some diseases are represented by more patients trying the therapy than others. As more patients join the MP cohort, the Autoimmunity Research Foundation will gather more data about the efficacy of the treatment with respect to individual diseases. In the meantime, the MP may be an appropriate treatment option for some of the diseases listed below. | Some diseases are represented by more patients trying the therapy than others. As more patients join the MP cohort, the Autoimmunity Research Foundation will gather more data about the efficacy of the treatment with respect to individual diseases. In the meantime, the MP may be an appropriate treatment option for some of the diseases listed below. | ||
- | [[home: | + | [[home: |
===== What is a chronic inflammatory disease? ===== | ===== What is a chronic inflammatory disease? ===== | ||
Line 37: | Line 37: | ||
Although patients who become infected with the Th1 pathogens are given a variety of diagnoses, there are often no clear cut distinctions between one disease and the next. Rather, symptoms frequently overlap creating a spectrum of illness in which diseases are more connected to one another than mutually exclusive disease states. | Although patients who become infected with the Th1 pathogens are given a variety of diagnoses, there are often no clear cut distinctions between one disease and the next. Rather, symptoms frequently overlap creating a spectrum of illness in which diseases are more connected to one another than mutually exclusive disease states. | ||
+ | |||
+ | ===== Microbial communication ===== | ||
+ | |||
+ | Here we show that an EHEC luxS mutant, unable to produce the bacterial autoinducer, | ||
+ | |||
+ | The contribution of cell-cell signaling and motility to bacterial biofilm formation. | ||
+ | | ||
+ | Bacterial Biofilm Control by Perturbation of Bacterial Signaling Processes.(({{pmid> | ||
+ | | ||
+ | |||
+ | |||
===== List of diseases ===== | ===== List of diseases ===== | ||
Line 52: | Line 63: | ||
+ | < | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
Line 107: | Line 119: | ||
- | < | + | < |
| | ||
more options | more options | ||
Line 140: | Line 152: | ||
PMS: | PMS: | ||
- | http:// | + | https:// |
- | < | + | < |
</ | </ | ||
Line 168: | Line 180: | ||
< | < | ||
Date: 2011-05-10 13:23:42 | Date: 2011-05-10 13:23:42 | ||
- | Reply: | + | Reply: |
Korean J Urol. 2011 vol. 52(3) pp. 194-9 | Korean J Urol. 2011 vol. 52(3) pp. 194-9 | ||
Line 190: | Line 202: | ||
From: ChrisMavo | From: ChrisMavo | ||
Date: 2011-05-10 13:29:58 | Date: 2011-05-10 13:29:58 | ||
- | Reply: | + | Reply: |
Can someone explain what they mean by nanobacteria? | Can someone explain what they mean by nanobacteria? | ||
Line 201: | Line 213: | ||
From: Bane | From: Bane | ||
Date: 2011-05-10 14:14:45 | Date: 2011-05-10 14:14:45 | ||
- | Reply: | + | Reply: |
ChrisMavo wrote: Can someone explain what they mean by nanobacteria? | ChrisMavo wrote: Can someone explain what they mean by nanobacteria? | ||
Line 209: | Line 221: | ||
- | http:// | + | https:// |
</ | </ | ||
Line 217: | Line 229: | ||
High levels of Epstein–Barr virus in COPD | High levels of Epstein–Barr virus in COPD | ||
- | http:// | + | https:// |
Line 238: | Line 250: | ||
- | http:// | + | https:// |
Line 264: | Line 276: | ||
From: LeeDate: 2011-11-01 07:44:01 | From: LeeDate: 2011-11-01 07:44:01 | ||
- | Reply: | + | Reply: |
Line 277: | Line 289: | ||
From: eClaire | From: eClaire | ||
Date: 2011-11-01 11:07:07 | Date: 2011-11-01 11:07:07 | ||
- | Reply: | + | Reply: |
Line 296: | Line 308: | ||
PMID: 21376827 | PMID: 21376827 | ||
- | </ | + | </ |